FDA gives Genentech’s Gazyva Priority Review for primary membranous nephropathy
FDA Priority Review puts Genentech’s Gazyva on a November decision path in primary membranous nephropathy after the Phase III MAJESTY win.
Pharma & Biotech
Pharma & Biotech
Roche ends two Huntington’s disease programmes after separate clinical setbacks
Roche Holding AG has discontinued development of tominersen and RG6496, removing two investigational huntingtin-lowering medicines from its neurology pipeline after separate setbacks emerged almost simultaneously. The Phase 2 GENERATION HD2 trial showed that tominersen lowered important biological markers but did not meaningfully slow clinical decline, while the Phase 1 POINT-HD study of RG6496 was halted
Pharma & Biotech
Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead
Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.
Pharma & Biotech
Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Pharma & Biotech
Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment
Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.
Pharma & Biotech
Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Pharma & Biotech
Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Pharma & Biotech
Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.